Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or primary clinical data
PubMed 33655857 · doi:10.2174/1566523221666210303100805
What was done
This narrative review synthesized literature on Hutchinson-Gilford progeria syndrome (HGPS), covering LMNA gene mutations, progerin production, downstream cellular pathophysiology, current treatment modalities, and potential therapeutic strategies.
What was found
The abstract reports no quantitative data or numerical outcomes. It describes the mechanistic cascade whereby abnormal LMNA splicing generates progerin, leading to nuclear structural abnormalities, DNA repair defects, telomere shortening, gene dysregulation, and accelerated premature aging.
Why it matters
The paper summarizes the molecular and pathophysiological basis of HGPS to inform the development of targeted therapeutic interventions for this fatal disorder.
Limits
The abstract provides no primary clinical or experimental data, sample sizes, or quantitative metrics. As a narrative review, it lacks systematic search methodology and formal risk-of-bias evaluation.
Cited by
- supports In children with progeria, an LMNA gene defect causes excess progerin production which degrades telomeres at chromosome ends.